This website is intended for UK healthcare professionals only Log in | Register

News and views

November 2018 Br J Cardiol 2018;25:131–132

Future advances in bifurcation stenting?

Less than 5% of interventional cardiologists attempt left main bifurcation percutaneous coronary intervention stenting procedures because it is so complicated, according to estimates from Advanced Bifurcation Systems (ABS), a US medical device company with a patented bifurcation stenting platform....

November 2018 Br J Cardiol 2018;25:131–132

Peripheral arterial disease assessment training tool

Clinicians who use handheld devices to ‘listen’ to the blood flow in patients’ lower limbs now have an online teaching aid that will improve their diagnostic skills in this area....

November 2018 Br J Cardiol 2018;25:133

In brief

Topics covered in brief in this issue include: self-monitoring of type 2 diabetes cuts costs; rivaroxaban licensed in patients with CAD or PAD; new cardiovascular ultrasound platform; CV meta-analysis shows SGLT2 inhibitor benefits; dairy fat linked to lower rates of CVD and mortality....

News from ESC 2018: Not all HDL cholesterol is cardioprotective

October 2018 Br J Cardiol 2018;25:135–7 Online First

News from ESC 2018: Not all HDL cholesterol is cardioprotective

Very high levels of high-density lipoprotein (HDL), the lipid that has been considered ‘good’ cholesterol, may be associated with an increased risk of heart attack and death, according to research presented at the ESC Congress....

October 2018 Br J Cardiol 2018;25:135–7 Online First

News from ESC 2018: COMMANDER HF – rivaroxaban in heart failure…

Rivaroxaban, the direct oral, factor Xa inhibitor, does not reduce the risk of a composite end point of survival, myocardial infarction (MI) and stroke after an episode of worsening heart failure in patients with heart failure, sinus rhythm, and coronary artery disease....

October 2018 Br J Cardiol 2018;25:135–7 Online First

News from ESC 2018: …and in VTE in the MARINER trial

The use of the oral anticoagulant rivaroxaban in medically ill patients for 45 days following hospital discharge showed there was no significant difference between rivaroxaban and placebo for the primary efficacy end point: a composite of symptomatic venous thromboembolism (VTE) and VTE-related death in the MARINER (Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness) study....

October 2018 Br J Cardiol 2018;25:135–7 Online First

News from ESC 2018: Is it safe for women with heart disease to become pregnant?

“Usually”, appears to be the answer according to 10-year results from the Registry Of Pregnancy And Cardiac disease (ROPAC) a worldwide, prospective registry which was set up in 2007 by co-chairs Professor Roos-Hesselink (Erasmus Medical Centre, Rotterdam, the Netherlands) and Professor Roger Hall (University of East Anglia, Norwich, UK)....

News from the 10th British Society for Heart Failure Day for revalidation and training

October 2018 Br J Cardiol 2018;25(4) Online First

News from the 10th British Society for Heart Failure Day for revalidation and training

‘All you need to know about heart failure – in one day’ was the promise of the 10th British Society for Heart Failure day for revalidation and training held on 19th June 2018 in Birmingham. The day provided a whistle-stop tour through the landscape of heart failure including drugs, devices, comorbidities, revascularisation and transplantation. Dr Andrew D’Silva reports some of the highlights....

October 2018 Br J Cardiol 2018;25:135–7 Online First

European Society of Cardiology 2018 Congress in briefs

This year’s meeting of the European Society of Cardiology (ESC) was held in Munich, Germany, from 25th–29th August 2018....

August 2018 Br J Cardiol 2018;25:95 Meeting report

HEART UK – Hot topics in atherosclerosis and cardiovascular disease

This year’s 32nd HEART UK Annual Medical and Scientific Conference reflects the current challenges and innovations within the lipid community. Whilst bringing variety to the programme with a number of hot topics, each area was skilfully explored by the speakers and audience bringing greater insight and direction to our management of cardiovascular disease. Jaqui Walker reports from the conference, held at the University of Warwick from July 4th–6th 2018....

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now